业绩与临床数据催化密集！港股通创新药ETF(159570)回调超1.5%！机构盘点：2026年创新药投资三大主线！

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a pullback, with the Hong Kong Stock Connect innovative drug ETF (159570) declining over 1.5%, despite a net inflow of over 14 million yuan [1][4]. Fund Performance - The innovative drug ETF has seen a cumulative capital inflow of over 360 million yuan in the past 10 days, with a total scale exceeding 25 billion yuan, leading in its category [1]. - As of February 13, 2026, the ETF has increased by over 70% since the second half of 2023, outperforming the Hong Kong pharmaceutical index [9][10]. Market Dynamics - Major stocks within the ETF, such as CSPC Pharmaceutical Group and BeiGene, have experienced declines of over 3%, while companies like Kangfang Biotech have shown slight gains [2][4]. - The innovative drug sector is expected to see a recovery driven by upcoming performance disclosures and clinical data releases in the near term [3]. Investment Opportunities - According to Guojin Securities, the innovative drug sector is poised for recovery due to a significant number of clinical data catalysts and the successful overseas clinical progress of pipelines [3]. - The number of License-out transactions for new drugs in China is projected to reach 158 by 2025, with a total transaction value of 135.7 billion USD, marking a decade-high in both quantity and value [3]. Clinical Data and Commercialization - Key clinical data releases are anticipated in 2025, with significant results expected from drugs like AK112 and IBI363, which could positively impact market valuations [7]. - The commercialization of innovative drugs is supported by recent policy measures aimed at enhancing the development of innovative pharmaceuticals [6].